Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas

• Published in: Biomedicine & pharmacotherapy 2024-10, Vol.179, p.117328, Article 117328
• Main Authors: Cui, Minghua, Liu, Yuehui, Liu, Yangyang, Li, Tao, Chen, Xin, Da, Liu
• Format: Article
• Language: English
• Subjects: Endocrine therapy; Endometrial cancer; Endometrioid adenocarcinoma; Nanopreparation; Oral delivery
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2024.117328

Endometrial cancer is one of the three major malignant tumors of the reproductive system that threaten women’s lives and health. The incidence of this disease is on the rise globally. Most cases of endometrial cancer comprise endometrioid adenocarcinomas, whose treatment is challenged by factors such as their high recurrence rate and the need to preserve fertility among young patients. Thus, oral endocrine therapy has become the main treatment modality. The main drugs used in oral endocrine therapy are progestins, selective estrogen receptor antagonists, and aromatase inhibitors. However, their clinical use is hindered by their low solubility and low oral utilization. The rapid development of nanotechnology allows the combination of these drugs with oral nano-formulations to create a good carrier. Such nanocarriers, including nanospheres, nanocapsules, and micelles can protect the drug against clearance and increase the site specificity of drug delivery. This paper reviews the pathogenesis of endometrioid endometrial cancer (EEC) and oral nano-formulations for endocrine therapy.